Get the Stockscreener App
4.7149
0.32%
0.0249
Cytek Biosciences Inc stock is traded at $4.7149, with a volume of 221.12K.
It is up +0.32% in the last 24 hours and up +1.84% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
See More
Previous Close:
$4.69
Open:
$4.66
24h Volume:
221.12K
Relative Volume:
0.16
Market Cap:
$612.87M
Revenue:
$204.17M
Net Income/Loss:
$-74.00M
P/E Ratio:
-8.1643
EPS:
-0.5775
Net Cash Flow:
$-12.84M
1W Performance:
+0.97%
1M Performance:
+1.84%
6M Performance:
+12.02%
1Y Performance:
+17.33%
1-Day Range:
$4.57
$4.735
1-Week Range:
$4.53
$4.935
52-Week Range:
$3.28
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.715 | 609.62M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
110.12 | 192.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
332.32 | 130.11B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
90.64 | 116.83B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.55 | 75.11B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.80 | 52.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek (CTKB) Q2 2026 Earnings Call Transcript - AOL.com
Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer - Stock Titan
Cytek Biosciences: Recurring Revenue Reaches 35% Of Sales As Installed Base Approaches 4,000 Instruments - Pulse 2.0
Cytek Biosciences launches Aurora Evo system to drive high-throughput research and small particle detection - Traders Union
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Cytek Biosciences (NASDAQ:CTKB) Trading 8.5% HigherShould You Buy? - marketbeat.com
Cytek Biosciences, Inc. (8EQ.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Cytek Biosciences, Inc. (CTKB) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A - Stock Titan
Cytek Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Morgan Stanley Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
TD Cowen Maintains Cytek Biosciences(CTKB.US) With Hold Rating, Maintains Target Price $5 - Moomoo
Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ... - Yahoo! Finance Canada
Cytek Biosciences Q2 2026 Earnings Report: Financial Highlights, Revenue Growth, and Investor Insights - Minichart
CTKB Looks 28.3% Undervalued on GF Value™ Despite Unprofitable S - GuruFocus
Cytek Biosciences (NASDAQ:CTKB) Posts Earnings Results, Hits Estimates - marketbeat.com
Cytek Biosciences Q2 Earnings Call Highlights - MarketBeat
Cytek Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cytek Biosciences earnings missed, revenue fell short of estimates - Investing.com
Earnings call transcript: Cytek Biosciences posts q2 2026 revenue growth, shares fall - Investing.com Nigeria
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Cytek Biosciences (CTKB) Releases Q2 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
Cytek Biosciences, Inc. 2Q 2026: Revenue $48.14M, EPS ($0.09) — 10-Q Summary - TradingView
Cytek Biosciences Q2 2026: Revenue $48.1M, Gross Profit $28.3M, Net Loss $12.2M - TradingView
Cytek Biosciences, Inc. Raising Revenue Guidance for the Full Year 2026 - marketscreener.com
Cytek Biosciences Reports Second Quarter 2026 Financial Results - The Manila Times
Cytek Biosciences Q2 GAAP net loss widens to $12.2 million; revenue rises 6% year over year to $48.1 million - Bitget
Cytek Biosciences (CTKB) Dips 2.3% to $4.18 as Support at $3.97 Comes into FocusMA Cross Alert - dars.gov.et
Cytek Biosciences incentivizes larger reagent purchases with free summer gifts - Traders Union
Boston Partners (CTKB) discloses 7.64M-share beneficial stake in Cytek Biosciences - stocktitan.net
Cytek Biosciences, Inc. expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cytek Biosciences (CTKB) Expected to Release Quarterly Earnings on Wednesday - marketbeat.com
Cytek Biosciences, Inc. Revenue Breakdown – TRADEGATE:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Cash Flow - TradingKey
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences Inc (CTKB) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
CTKB|Cytek Biosciences Inc|Price:4.420|Chg%:-0.040 - TradingKey
Cytek Biosciences, Inc. Revenue Breakdown – FWB:8EQ - TradingView
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences (CTKB) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Shares SlipROE Trend Analysis - po-news-eg.net
Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making - Traders Union
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
CTKB stock rises as Cytek BioSciences reports revenue and margin trends - Ad-hoc-news.de
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026 - The Manila Times
Cytek Biosciences to report Q2 2026 results on August 5 - scanx.trade
Cytek Biosciences sets Q2 results call for 4:30 p.m. ET Aug. 5 - Stock Titan
Cytek Biosciences reveals special summer incentive for reagent customers - Traders Union
Cytek Bio stock trades steadily as Q1 2026 growth and margin profile frame investor focus - Ad-hoc-news.de
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - BioSpace
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement - Finviz
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):